Excision BioTherapeutics Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

10 Apr 2024
www.biospace.com
Gene TherapyClinical Study
Excision to give three oral presentations and outline new data in three posters from preclinical programs for herpes keratitis (HSV-1 Keratitis) and hepatitis B virus (HBV) as well as a next-generation AAV vector Update on the EBT-101 first-in-human trial to be presented in an oral session SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Excision BioTherapeutics Inc. (“Excision”, the “Company”), a clinical-stage biotechnology company developing CRISPR-based therapies to cure serious latent viral infectious diseases, today announced presentation of six abstracts at the ASGCT 2024 Annual Meeting, which is being held from May 7-11, 2024 in Baltimore, Maryland. The presentations are related to new data for the Company’s emerging preclinical programs for herpes simplex virus-1 keratitis (HSV-1 Keratitis) and hepatitis B virus (HBV), as well as an overview of a next generation AAV delivery vector. In addition, there will be an update on the Company’s first-in-human study of EBT-101. Presentation details: Oral Presentations Title:Non-Viral Gene Editing with Dual Guide RNAs for Chronic Hepatitis B Infection Excision Program: HBV Session Type: Oral presentation Session Title: Gene Disruption and Excision Abstract: 153 Presenter: Ryo Takeuchi, Excision BioTherapeutics Location: Ballroom 3 Date/Time: May 09, 2024, 2:21 to 2:38 pm (EST) Title:Selecting highly conserved and specific guide RNAs for CRISPR/CasX-mediated gene editing of the HSV-1 genome Excision Program: HSV-1 Keratitis Session Type: Oral presentation Session Title: On- and Off-target Method Development Abstract: 256 Presenter: Meltem Isik, Excision BioTherapeutics Location: Ballroom 3 Date/Time: May 10, 2024, 2:00 to 2:15 pm (EST) Title:EBT-101: First-in-human clinical trial of systemic CRISPR-CA9 multiplex targeting of Latent HIV Excision Program: HIV Session Type: Oral presentation Location: Ballroom 2 Date/Time: May 10, 2024, 9:18 AM to 9:44 AM (EST) Presentation details: Poster Presentations Title:CRISPR/CasX-Mediated Gene Editing as a Therapeutic Approach for HSV-1 Keratitis Excision Program: HSV-1 Keratitis Session Type: Poster presentation Session Title: Gene Disruption and Excision Abstract: 1188 Presenter: Guoxiang Ruan, Excision BioTherapeutics Location: Exhibit Hall Date/Time: May 09, 2024, 5:30 to 7:00 pm (EST) Title:Develop Next Generation All-in-One AAV Vectors for CRISPR/Cas Gene Editing with Paired Guide RNAs Excision Program: Next Generation Vectors Session Type: Poster presentation Session Title: AAV Vectors – Virology and Vectorology Abstract: 966 Presenter: Wenwen Huo, Excision BioTherapeutics Location: Exhibit Hall Date/Time: May 09, 2024, 5:30 to 7:00 pm (EST) Title:CRISPR/Cas9-mediated gene editing for herpes simplex virus reduces viral reactivation in a latent rabbit keratitis model Excision Program: HSV-1 Keratitis Session Type: Poster presentation Session Title: Ophthalmic and Auditory Diseases Abstract: 1633 Presenter: Nadia Amrani, Excision BioTherapeutics Location: Exhibit Hall Date/Time: May 10, 2024, 5:30 to 7:00 pm (EST) About Excision BioTherapeutics, Inc. Excision BioTherapeutics, Inc. develops CRISPR-based medicines as potential cures for serious viral latent infectious diseases based its proprietary multiplexed gene editing platform that unites next-generation CRISPR nucleases with a novel gene editing approach to develop curative therapies. The Company’s pipeline targets large, underserved markets including herpes simplex virus-1 keratitis (HSV-1 keratitis), hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1). Excision’s foundational technologies were developed in the laboratories of Dr. Kamel Khalili at Temple University and Dr. Jennifer Doudna at the University of California, Berkeley. For more information, please visit . Contact: John Fraunces LifeSci Advisors 917-355-2395 jfraunces@lifesciadvisors.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.